What is Glivec®?
Glivec® is a medicine discovered and developed by Novartis for the treatment of
Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) and c-kit
(CD117) positive unresectable (inoperable) and/or metastatic malignant gastrointestinal
stromal tumours (GIST). Glivec® is one of the first cancer drugs that validate rational
drug design, based on an understanding of how some cancer cells function.
Glivec® is approved in over 80 countries for the treatment of adult patients with
Ph+ CML in blast crisis, accelerated phase, or in chronic phase. Glivec® is also
approved for the treatment of newly diagnosed Ph+ CML in the EU, U.S. and Japan
and a number of other markets. Marketing approval in the EU, Switzerland and other
countries includes the treatment of pediatric patients.
In 2002, Glivec® was also approved for treatment of patients with c-kit (CD 117)
positive unresectable (inoperable) and/or metastatic malignant gastrointestinal
stromal tumours (GIST) in the EU, U.S. and more than 45 other countries.
For more information about Glivec®, please visit the Glivec® international Site